{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:26:07Z","timestamp":1777616767778,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.phrs.2015.07.033","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T19:18:06Z","timestamp":1438456686000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors"],"prefix":"10.1016","volume":"100","author":[{"given":"Peter","family":"Heusler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Cussac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Naline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Clerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.07.033_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2015.07.033_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pupt.2012.12.006","article-title":"Long-acting muscarinic receptor antagonists for the treatment of respiratory disease","volume":"26","author":"Cazzola","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12325-010-0017-6","article-title":"The short, the long and the ultra-long: why duration of bronchodilator action matters in chronic obstructive pulmonary disease","volume":"27","author":"Beeh","year":"2010","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0020","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.rmed.2013.08.007","article-title":"Long-acting bronchodilators improve health related quality of life in patients with COPD","volume":"107","author":"Braido","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.phrs.2015.07.033_bib0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.rmed.2013.08.003","article-title":"The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients","volume":"108","author":"Kim","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.phrs.2015.07.033_bib0030","unstructured":"GOLD, Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease 2014. Available from: <http:\/\/www.goldcopd.org\/> (2014)."},{"key":"10.1016\/j.phrs.2015.07.033_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)01728-4","article-title":"Beta-adrenoceptor agonists and asthma\u2013100 years of development","volume":"445","author":"Waldeck","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0024-3205(98)00588-8","article-title":"Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease","volume":"64","author":"Disse","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2015.07.033_bib0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2332\/allergolint.09-RAI-0117","article-title":"Pharmacological treatment in asthma and COPD","volume":"58","author":"Hoshino","year":"2009","journal-title":"Allergol. Int."},{"key":"10.1016\/j.phrs.2015.07.033_bib0050","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.drudis.2014.08.004","article-title":"Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping","volume":"19","author":"Montuschi","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2015.07.033_bib0055","first-page":"833","article-title":"Use of inhaled anticholinergic agents in obstructive airway disease","volume":"52","author":"Restrepo","year":"2007","journal-title":"Respir. Care"},{"key":"10.1016\/j.phrs.2015.07.033_bib0060","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0024-3205(93)90312-Q","article-title":"Ba 679 BR, a novel long-acting anticholinergic bronchodilator","volume":"52","author":"Disse","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2015.07.033_bib0070","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.bjp.0706819","article-title":"Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor","volume":"148","author":"Dowling","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","article-title":"The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium","volume":"343","author":"Sykes","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0080","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1111\/j.1476-5381.2011.01639.x","article-title":"Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists","volume":"165","author":"Sykes","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"June","key":"10.1016\/j.phrs.2015.07.033_bib0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12931-015-0227-1","article-title":"V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results","volume":"16","author":"Devillier","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.phrs.2015.07.033_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)15016-5","article-title":"The kinetics of competitive radioligand binding predicted by the law of mass action","volume":"25","author":"Motulsky","year":"1984","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0095","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0022-3565(24)38060-7","article-title":"Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase","volume":"288","author":"Teschemacher","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1183\/09031936.94.07050914","article-title":"Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus","volume":"7","author":"Naline","year":"1994","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2015.07.033_bib0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pupt.2005.02.014","article-title":"Effect of cold storage on cholinergic responses induced by electrical field stimulation in human bronchi","volume":"19","author":"B\u00e4ck","year":"2006","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0110","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/bph.12597","article-title":"Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors","volume":"171","author":"Grassin-Delyle","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1183\/09031936.00032806","article-title":"Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi","volume":"29","author":"Naline","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2015.07.033_bib0120","series-title":"A Pharmacology Primer: Theory, Applications, and Methods","author":"Kenakin","year":"2010"},{"key":"10.1016\/j.phrs.2015.07.033_bib0125","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.110.170035","article-title":"Bronchodilator activity of (3R)-3[[[(3-fluorophenyl) [(3,4,5trifluorophenyl)methyl]amino]oxy]carbonyl]-1-[2-oxo-2-(2-thienyl) ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407) a potent, long-acting and selective muscarinic M3 receptor antagonist","volume":"335","author":"Villetti","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/pr.54.2.323","article-title":"G Protein-coupled receptor allosterism and complexing","volume":"54","author":"Christopoulos","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2015.07.033_bib0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.109.163188","article-title":"The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics","volume":"333","author":"Casarosa","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0140","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/jpet.109.151639","article-title":"Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile","volume":"331","author":"Gavalda","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.033_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2009.07.022","article-title":"Ligands, their receptors and plasma membranes","volume":"311","author":"Vauquelin","year":"2009","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0155","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1476-5381.2010.01087.x","article-title":"Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations","volume":"162","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuint.2007.05.005","article-title":"Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation","volume":"51","author":"Vauquelin","year":"2007","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2015.07.033_bib0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1476-5381.2009.00370.x","article-title":"On the mechanism of the persistent action of salmeterol: what is the current position?","volume":"158","author":"Coleman","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1476-5381.2009.00296.x","article-title":"Molecular mechanisms for the persistent bronchodilatory effect of the beta2-adrenoceptor agonist salmeterol","volume":"158","author":"Szczuka","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.033_bib0175","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1021\/jm100068m","article-title":"The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist","volume":"53","author":"Baur","year":"2010","journal-title":"J. Med. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T21:05:31Z","timestamp":1748552731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":35,"alternative-id":["S1043661815001668"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.07.033","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}